Outlook Therapeutics (OTLK) insider-linked entity buys 2.5M shares plus 2.5M warrants
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. insider GMS Ventures & Investments, associated with director and 10% owner Ghiath M. Sukhtian, participated in an underwritten public offering on August 12, 2026. GMS Ventures purchased 2,525,252 shares of common stock at $0.99 per share and received accompanying warrants to purchase 2,525,252 shares of common stock at an exercise price of $1.10 per share. The warrants were issued for $0.00 as part of the combined public offering price, are exercisable immediately, and expire on August 14, 2031 subject to a beneficial ownership limitation. Following the stock purchase, GMS Ventures held 24,617,320 shares of Outlook Therapeutics common stock indirectly reported for Sukhtian, with both reporting persons disclaiming beneficial ownership beyond their pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 2,525,252 shares
Net Buy
2 txns
Insider
Sukhtian Ghiath M., GMS Ventures & Investments
Role
Director, 10% Owner | Director, 10% Owner
Bought
5,050,504 shs ($2.50M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants (right to buy) F1, F2, F3, F4 | 2,525,252 | $0.00 | $0.00 |
| Purchase | Common Stock F1, F3, F4 | 2,525,252 | $0.99 | $2.50M |
Holdings After Transaction:
Warrants (right to buy) — 2,525,252 shares (Indirect, See footnote);
Common Stock — 24,617,320 shares (Indirect, See footnote)
Footnotes (4)
- F1. On August 12, 2026, the Issuer entered into an underwriting agreement with Piper Sandler & Co. and BTIG, LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering by the Issuer of shares of its common stock and accompanying warrants to purchase shares of common stock at a combined public offering price of $0.99 per share of common stock and accompanying warrant. The offering closed on August 14, 2026. The price reported in Table I above represents the combined public offering price for one share of common stock and one accompanying warrant to purchase one share of common stock; no separate consideration was paid for the accompanying warrants, and accordingly the price of the derivative security reported in Table II above is $0.00.
- F2. The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031. The warrants are subject to a beneficial ownership limitation that prohibits exercise to the extent the holder, together with its affiliates and other attribution parties, would beneficially own more than the applicable percentage of the Issuer's outstanding common stock immediately after giving effect to such exercise.
- F3. These securities are held of record by GMS Ventures. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated two representatives to serve on the Issuer's board of directors. Therefore, each of GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization.
- F4. By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owners of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Key Figures
Common shares purchased: 2,525,252 shares
Purchase price per share: $0.99
Warrant underlying shares: 2,525,252 shares
+4 more
7 metrics
Common shares purchased
2,525,252 shares
Indirect purchase by GMS Ventures on August 12, 2026
Purchase price per share
$0.99
Combined public offering price for one share and one warrant
Warrant underlying shares
2,525,252 shares
Warrants to buy Outlook Therapeutics common stock
Warrant exercise price
$1.10 per share
Exercise price for the accompanying warrants
Warrant consideration
$0.00
No separate consideration paid for warrants in combined price
Warrant expiration date
August 14, 2031
Five years from date of issuance
Shares held after transaction
24,617,320 shares
Indirect common stock holdings by GMS Ventures after purchase
Key Terms
underwriting agreement, underwritten public offering, warrants, beneficial ownership limitation, +2 more
6 terms
underwriting agreement financial
"entered into an underwriting agreement with Piper Sandler & Co. and BTIG, LLC"
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
underwritten public offering financial
"relating to an underwritten public offering by the Issuer of shares"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
warrants financial
"accompanying warrants to purchase shares of common stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
beneficial ownership limitation regulatory
"The warrants are subject to a beneficial ownership limitation that prohibits exercise"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
beneficially own regulatory
"may be deemed to beneficially own such securities for purposes of Rule 13d-3"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest financial
"except to the extent of its or his pecuniary interest therein, if any"
FAQ
What did insider GMS Ventures buy in Outlook Therapeutics (OTLK)?
GMS Ventures bought 2,525,252 shares of Outlook Therapeutics common stock at $0.99 per share in an underwritten public offering on August 12, 2026, as reported indirectly for Ghiath M. Sukhtian.
What warrants did GMS Ventures receive in the OTLK transaction?
GMS Ventures received warrants for 2,525,252 shares of Outlook Therapeutics common stock with a $1.10 exercise price, exercisable immediately and expiring on August 14, 2031, issued for $0.00 as part of the combined public offering price.
What was the combined public offering price in the OTLK deal?
The combined public offering price was $0.99 for one Outlook Therapeutics common share and one accompanying warrant, with no separate consideration paid for the warrant, according to the Form 4 footnote disclosure.
Is there a beneficial ownership limitation on the OTLK warrants?
Yes. The warrants are subject to a beneficial ownership limitation that restricts exercise if the holder and its affiliates would exceed a specified percentage of Outlook Therapeutics’ outstanding common stock immediately after exercise.
Were the OTLK insider purchases under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as a plan trade, and the footnotes describe participation in an underwritten public offering rather than a pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
